Patent · US Active

Vaccines against Zika virus

US12419945B2 · kind B2 · utility

0Cited by
1References
17Claims
0Family size

Assignees

Inventors

Key dates

Filing dateMay 16, 2023
Grant dateSep 23, 2025
Priority date
Expiry dateMay 16, 2043

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

An aspect of the present invention is related to nucleic acid constructs capable of expressing a Zika antigen that elicits an immune response in a mammal against Zika virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a Zika virus, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a Zika antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal that is cross reactive against all Zika strains.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.